Strategic Partnerships Explore a collaboration with Zelluna Immunotherapy AS to accelerate UV1 and TET platform development, leveraging combined capabilities and potential private placement to secure growth funding and broader clinical reach.

Clinical Expansion Target collaborations or licensing deals with biopharma to advance UV1 in multiple tumor types and across regions (Europe, US, Australia), using the broad Phase II program as evidence of oncology potential and market interest.

Clinical Milestones Position UV1 and the TET platform around upcoming trial readouts and dataset disclosures to create investor and partner urgency, offering co-development or milestone-based financing aligned with trial progress.

Immunotherapy Synergy Highlight UV1 as a combinatorial partner for established IO drugs to enhance T cell responses, enabling potential multi-drug regimens with partners seeking to extend durability of responses in melanoma, mesothelioma, H&N, ovarian, and NSCLC.

Resource Leverage Leverage publicly listed status and Nordic operations to attract regional licensing or consulting collaborations, emphasizing access to a focused pipeline, experienced CSO leadership, and proximity to European clinical networks.